Boston, Massachusetts, United States In 1983 was created Fletcher Spaght, Inc., which is appeared as VC. The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Software, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Proteus Digital Health, Juventas Therapeutics, Cayenne Medical.
The fund is constantly included in less than 2 deals per year. This Fletcher Spaght, Inc. works on 6 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 10 percentage points less often commits exit comparing to other companies. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2011. The top amount of exits for fund were in 2015.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Fletcher Spaght, Inc., startups are often financed by The Aurora Funds, Sevin Rosen Funds, Schroder Ventures. The meaningful sponsors for the fund in investment in the same round are Hatteras Venture Partners, The Aurora Funds, New Enterprise Associates. In the next rounds fund is usually obtained by Silicon Valley Bank, New Enterprise Associates, Hatteras Venture Partners.
The fund was created by John Fletcher, Linda Tufts. We also calculated 7 valuable employees in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 20 North Street | - |
| Baituan Touzi | Beijing, Changping, China |
| Branding Engineer | Japan, Kanagawa Prefecture, Yamato |
| Elite Partners Capital | Central Region, Singapore, Singapore |
| Fengsong Touzi | China, Jinshan District |
| Ginni International | China, Hong Kong, Hong Kong Island |
| Inventure Capital, Madison | Madison, United States, Wisconsin |
| Jimin Touzi | China, Hangzhou, Zhejiang |
| Kester Capital | England, London, United Kingdom |
| Lang Sheng Investment | China, Shanghai |
| McWin | - |
| Meiya Pico | China, Fujian, Xiamen |
| National ICT R&D Fund | - |
| New Media Investment Group | New York, New York, United States |
| ROK Capital | - |
| Spieker Partners | - |
| Stream Global Services | Eagan, Minnesota, United States |
| Venture Garage | Delhi, India, New Delhi |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cheetah Medical | $11M | 12 Sep 2017 | Newton, Massachusetts, United States | ||
HistoSonics | $8M | 13 Mar 2017 | Minnesota, United States | ||
Swift Biosciences | $3M | 15 Apr 2016 | Ann Arbor, Michigan, United States | ||
PhaseBio Pharmaceuticals | $40M | 12 Mar 2015 | Pennsylvania, United States | ||
Cheetah Medical | $28M | 24 Feb 2014 | Newton, Massachusetts, United States | ||
Swift Biosciences | $7M | 17 Oct 2013 | Ann Arbor, Michigan, United States | ||
Juventas Therapeutics | $22M | 16 Jul 2012 | Cleveland, Ohio, United States | ||
PhaseBio Pharmaceuticals | $23M | 05 Jun 2012 | Pennsylvania, United States | ||
SironRX Therapeutics | $3M | 16 Aug 2011 | Cleveland, Ohio, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cheetah Medical | $11M | 12 Sep 2017 | Newton, Massachusetts, United States | ||
HistoSonics | $8M | 13 Mar 2017 | Minnesota, United States | ||
Swift Biosciences | $3M | 15 Apr 2016 | Ann Arbor, Michigan, United States | ||
PhaseBio Pharmaceuticals | $40M | 12 Mar 2015 | Pennsylvania, United States | ||
Cheetah Medical | $28M | 24 Feb 2014 | Newton, Massachusetts, United States | ||
Swift Biosciences | $7M | 17 Oct 2013 | Ann Arbor, Michigan, United States | ||
Juventas Therapeutics | $22M | 16 Jul 2012 | Cleveland, Ohio, United States | ||
PhaseBio Pharmaceuticals | $23M | 05 Jun 2012 | Pennsylvania, United States | ||
SironRX Therapeutics | $3M | 16 Aug 2011 | Cleveland, Ohio, United States |
